Trial reportBMC psychiatry2026
Risperidone for children with attention-deficit/hyperactivity disorder and severe behavioral dysregulation: a randomized placebo-controlled assessor-blinded trial.
Trial report in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAttention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in childhood, and treatment of children with severe behavioral dysregulation remains challenging. This study evaluated the efficacy and safety of adjunctive risperidone specifically in children with ADHD and clinically significant behavioral dysregulation - including irritability, impulsive aggression, and oppositional symptoms - refractory to behavioral intervention alone.
methodsIn this 48-week randomized, placebo-controlled, assessor-blinded trial, children aged 3-12 years with moderate-to-severe ADHD and significant behavioral dysregulation refractory to behavioral intervention alone were allocated to risperidone (n = 48) or matched placebo (n = 46), both in addition to ongoing structured behavioral intervention and parental psychoeducation. The primary outcome was change in clinician-rated ADHD-RS-IV score from baseline to week 48. Secondary outcomes included parent-rated Conners' scores, Children's Global Assessment Scale (CGAS), treatment response, adverse events, and metabolic parameters.
resultsRisperidone produced a significantly greater reduction in ADHD-RS-IV scores than placebo over time (baseline: 28.85 ± 2.62 vs. 28.70 ± 2.50; week 48: 15.63 ± 1.82 vs. 26.47 ± 2.92; p < 0.001). Parent-rated Conners' scores also improved more in the risperidone group (week 48: 16.94 ± 1.81 vs. 28.42 ± 3.04; p < 0.001). Functional improvement was greater with risperidone, with higher CGAS scores and a higher clinical response rate (70.8% vs. 21.7%; p < 0.001). The most common adverse effects were somnolence and increased appetite. Risperidone was associated with greater weight gain and prolactin elevation than placebo, but no serious adverse events occurred.
conclusionIn this study, risperidone was associated with improvement in ADHD symptom severity and global functioning in carefully selected children with ADHD and prominent behavioral dysregulation. However, treatment was also associated with clinically relevant metabolic and endocrine adverse effects. These findings support selective use as a pharmacological adjunct to behavioral intervention in closely monitored patients with significant behavioral comorbidity, and do not justify routine use for uncomplicated ADHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.